Brean Murray assumes coverage on Sinovac Biotech (NYSE: SVA) with a Buy rating. Price target $11.

Brean analyst says, "Not ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE